TY - JOUR
T1 - Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: Comparing chemotherapy with nanotherapy
AU - Ferrandina, Maria Gabriella
AU - Scambia, Giovanni
AU - Bosetti, Rita
AU - Marneffe, Wim
AU - Vereeck, Lode
PY - 2014
Y1 - 2014
N2 - This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer.
AB - This article examines the cost-effectiveness of chemotherapy (gemcitabine) versus nanotherapy (PEGylated liposomal doxorubicin) in the treatment of ovarian cancer. Significant differences in costs were mainly due to the initial drug costs, which were €1285.28 in favor of chemotherapy. These costs were more than offset by hospitalization costs, which were €2670.21 in favor of the nanotherapy. The cost per quality-adjusted life week (QALW) for the nanotherapy was estimated to be €220.92/QALW for the base case and ranged from €170-318/QALW based on model assumptions. The clinical benefit associated with nanotherapy was achieved, yielding not only positive cost-effectiveness results, but also, surprisingly, financial savings. Although more studies are necessary, this first comprehensive analysis supports the further use of nanotherapy for ovarian cancer.
KW - gemcitabine vs PEGylated
KW - ovarian cancer
KW - gemcitabine vs PEGylated
KW - ovarian cancer
UR - http://hdl.handle.net/10807/63295
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84911491338&partnerid=40&md5=e14f84f567889c4f8cb4fa8612cdc256
M3 - Article
VL - 9
SP - 2175
EP - 2186
JO - Nanomedicine
JF - Nanomedicine
SN - 1743-5889
ER -